ILK-IN-2

Overview

ILK-IN-2 (OSU-T315 analog) is an oral PDK2 inhibitor and also an ILK inhibitor, with an IC 50 of 0.6 μM. ILK-IN-2 induces cell autophagy and apoptosis , showing anti-tumor activity. ILK-IN-2 directly abolishes AKT activation by preventing AKT from translocating to lipid rafts, triggering Caspase -dependent apoptosis in chronic lymphocytic leukemia (CLL) and extending the lifespan in TCL1 mouse models.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PDHK | Products > Signaling Pathways > Integrin | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Caspase

Product Information

• Catalog No.: HY-18676B
• CAS No.: 1333146-24-9
• Molecular Formula: C30H30F3N5O
• Molecular Weight: 533.59
• Purity: 98.79%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 5 mg/mL (9.37 mM); Clear solution
• Availability: In-stock

Source

Original product source